Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Syndax signs up Ventana to develop companion diagnostic for entinostat

Executive Summary

Ventana Medical Systems Inc., a division of Roche Diagnostics Corp. that focuses on anatomical pathology markets, has agreed to develop for Syndax Pharmaceuticals Inc. (cancer medicines targeting epigenetics) a companion diagnostic to select a unique patient population for treatment with erlotinib (Roche’s Tarceva) and Syndax’s lead candidate entinostat, which is about to enter Phase III for non-small cell lung cancer.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies